Hereditary Hemorrhagic Telangiectasia and Danazol

Letters and Corrections15 July 1988Hereditary Hemorrhagic Telangiectasia and DanazolAmin U. Haq, MD, Jonathan Glass, MD, Catherine V. Netchvolodoff, MD, L. Michael Bowen, MDAmin U. Haq, MD, Jonathan Glass, MD, Catherine V. Netchvolodoff, MD, L. Michael Bowen, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-2-171_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) is characterized by recurrent bleeding episodes, multiple telangiectasias, and familial occurrence. Treatment of this disease is unsatisfactory. Oral estrogen may be very useful in controlling the frequency and severity of epistaxis (1). However, due to the feminizing effects of estrogens, male patients may be reluctant to take the hormones. The authors were recently forced to search for an alternative treatment in a male patient who refused to take estrogen. There was marked improvement of symptoms with danazol, a synthetic weak androgen.A 41-year-old white army veteran had severe anemia; he had a...References1. Harrison D. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. 1982;92:314-20. CrossrefMedlineGoogle Scholar2. MenefeeFlessaGlueckHogg MHHS. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): an electron microscopic study of the vascular lesions before and after therapy with hormones. Arch Otolaryngol. 1975;101:246-51. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Amin U. Haq, MD; Jonathan Glass, MD; Catherine V. Netchvolodoff, MD; L. Michael Bowen, MDAffiliations: Veterans Administration Medical Center and Louisiana State University Medical Center Shreveport, LA 71130 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReview of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related BleedingBevacizumab as a treatment option in gastrointestinal bleeding associated to hereditary hemorrhagic telangiectasia. Case ReportIntravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal BleedingCurrent and emerging pharmacotherapies for hereditary hemorrhagic telangiectasiaBleeding recurrence in patients with gastrointestinal vascular malformation after thalidomideHow to manage patients with hereditary haemorrhagic telangiectasiaRefractory bleeding from intestinal angiodysplasias successfully treated with danazol in three patients with von Willebrand diseaseChronic Gastrointestinal BleedingLack of significant estrogen and progesterone receptor expression in nasal telangiectasias in hereditary hemorrhagic telangiectasia: An immunohistochemical analysisThe evaluation and management of obscure and occult gastrointestinal bleedingVascular Abnormalities of the Small BowelHormonal and Antihormonal Therapy for Epistaxis in Hereditary Hemorrhagic TelangiectasiaPharmacologic management of obscure gastrointestinal bleedingDiagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasiaHereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestationsIs oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluationAGA technical review on the evaluation and management of occult and obscure gastrointestinal bleedingPharmacologic Therapy of Arteriovenous MalformationsHereditary hemorrhagic telangiectasia: report of 15 affected cases in a Mexican family 15 July 1988Volume 109, Issue 2Page: 171-171KeywordsAndrogensAnemiaEstrogensGenetic diseasesHemorrhageHormones ePublished: 1 December 2008 Issue Published: 15 July 1988 PDF downloadLoading ...